3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Breast Neoplasms
4
Prostatic Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
NSCLC
1
Myelodysplastic Syndromes
1
Mucopolysaccharidosis I
1
Metastatic Castration-resistant Prostate Cancer
1
Metabolism, Inborn Errors
1
Mesothelioma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Non-Hodgkin
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Immunologic Deficiency Syndromes
1
Immunoblastic Lymphadenopathy
1
Hodgkin Disease
1
Hemoglobinopathies
1
Graft vs Host Disease
1
Disease Progression
1
Interventions
Pemetrexed
39
Cisplatin
33
pembrolizumab
21
Nivolumab
17
Carboplatin
16
Ipilimumab
13
Gemcitabine
10
Cyclophosphamide
9
fludarabine
6
durvalumab
6
Bevacizumab
6
Radiotherapy, Intensity-Modulated
4
LMB-100
4
Dexamethasone
4
tremelimumab
3
tazemetostat
3
spartalizumab
3
olaparib
3
niraparib
3
atezolizumab
3
anetumab ravtansine
3
amatuximab
3
Vinorelbine
3
Paclitaxel
3
Imatinib Mesylate
3
Cerebral Decortication
3
tislelizumab
2
sargramostim
2
fludarabine phosphate
2
defactinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Mesothelioma
×
Clinical Trials, Phase I as Topic
×
Clear all
NCT03655834
2022-05-10
IMPROVE-III
Radboud University Medical Center
Phase 4
Completed
10 enrolled